Study #2017-0671
Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types
MD Anderson Study Status
Enrolling
Treatment Agent
Autologous Tumor Infiltrating Lymphocytes MDA-TIL, Cyclophosphamide, Fludarabine, Fludarabine Phosphate, Interleukin-2
Description
This phase II trial studies how well autologous tumor infiltrating lymphocytes MDA-TIL works in treating patients with ovarian cancer, colorectal cancer, or pancreatic ductal adenocarcinoma that has come back (recurrent) or does not respond to treatment (refractory). Autologous tumor infiltrating lymphocytes MDA-TIL, made by collecting and growing specialized white blood cells (called T-cells) from a patient's tumor, may help to stimulate the immune system in different ways to stop tumor cells from growing.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
High Grade Ovarian Serous Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Oligometastasis, Ovarian Carcinosarcoma, Pancreatic Ductal Adenocarcinoma, Recurrent Colorectal Carcinoma, Recurrent Ovarian Carcinoma, Refractory Colorectal Carcinoma, Refractory Ovarian Carcinoma, Stage IV Colorectal Cancer AJCC v8
Study phase:
II
Physician name:
Amir Jazaeri
Department:
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials:
1-877-632-6789